Download PDF
Semin Thromb Hemost 2019; 45(08): 825-833
DOI: 10.1055/s-0039-1687911
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review

Fernanda A. Orsi
1   Department of Clinical Pathology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
2   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
,
Suzanne C. Cannegieter
2   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
3   Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
4   Department of Internal Medicine, Section of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Willem M. Lijfering
2   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
3   Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
› Author Affiliations Funding F.A.O. received financial support from São Paulo Research Foundation (FAPESP grant#2017/09506–5).
Further Information

Publication History

Publication Date:
16 May 2019 (online)

   Permissions and Reprints

Abstract

Venous thromboembolism (VTE) causes a major disease burden worldwide, so that effective preventive measures are warranted. Although oral anticoagulation is effective in preventing VTE episodes, bleeding complications are a major concern that may lead to treatment avoidance. Statin therapy, which is widely used for prevention of arterial cardiovascular disease, is a promising alternative treatment for VTE prophylaxis, as the drug may affect hemostasis without increasing the risk of bleeding. In the past years, clinical studies have suggested that statins can interfere with blood coagulation and, in turn, reduce the risk of VTE. These effects, however, are still regarded with skepticism, as the underlying mechanisms by which statins may affect hemostasis in humans are not clear and data showing that statin therapy reduces VTE risk mostly came from observational studies, while only one randomized trial was conducted to evaluate this issue. In this review, the authors summarize the currently available evidence regarding the effect of statin therapy on coagulation and on VTE prevention. Recent randomized data showed that statin therapy, in particular rosuvastatin, leads to decreased levels of coagulation factors in patients with prior VTE. This evidence provides a reasonable basis for interventional studies necessary to establish the efficacy of statins on reducing the risk of incident and recurrent VTE.

Keywords

blood coagulation - clinical trials - hydroxymethylglutaryl-CoA reductase inhibitors - prevention - venous thrombosis
 

  • References

  • 1 ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12 (10) 1580-1590
    CrossrefPubMedGoogle Scholar
  • 2 Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res 2016; 118 (09) 1340-1347
    CrossrefPubMedGoogle Scholar
  • 3 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. ; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
    CrossrefPubMedGoogle Scholar
  • 4 Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149 (06) 824-833
    CrossrefPubMedGoogle Scholar
  • 5 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 6 Becattini C, Agnelli G, Schenone A. , et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
    CrossrefPubMedGoogle Scholar
  • 7 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 8 Schulman S, Kearon C, Kakkar AK. , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedGoogle Scholar
  • 9 Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost 2014; 111 (03) 392-400
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Amarenco P, Bogousslavsky J, Callahan III A. , et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355 (06) 549-559
    CrossrefPubMedGoogle Scholar
  • 11 Collins R, Armitage J, Parish S, Sleight P, Peto R. ; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363 (9411): 757-767
    CrossrefPubMedGoogle Scholar
  • 12 Ridker PM, Danielson E, Fonseca FAH. , et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21) 2195-2207
    CrossrefPubMedGoogle Scholar
  • 13 Glynn RJ, Danielson E, Fonseca FA. , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18) 1851-1861
    CrossrefPubMedGoogle Scholar
  • 14 Hackam DG, Woodward M, Newby LK. , et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011; 124 (20) 2233-2242
    CrossrefPubMedGoogle Scholar
  • 15 Morgenstern LB, Hemphill III JC, Anderson C. , et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41 (09) 2108-2129
    CrossrefPubMedGoogle Scholar
  • 16 Zhang H, Plutzky J, Skentzos S. , et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158 (07) 526-534
    CrossrefPubMedGoogle Scholar
  • 17 Stone NJ, Robinson JG, Lichtenstein AH. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (25 Pt B): 2889-2934
    CrossrefPubMedGoogle Scholar
  • 18 Mahmoodi BK, Cushman M, Anne Næss I. , et al. Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta-analysis of prospective studies. Circulation 2017; 135 (01) 7-16
    CrossrefPubMedGoogle Scholar
  • 19 Zöller B, Li X, Sundquist J, Sundquist K. Socioeconomic and occupational risk factors for venous thromboembolism in Sweden: a nationwide epidemiological study. Thromb Res 2012; 129 (05) 577-582
    CrossrefPubMedGoogle Scholar
  • 20 Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89 (03) 493-498
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Roach RE, Lijfering WM, Flinterman LE, Rosendaal FR, Cannegieter SC. Increased risk of CVD after VT is determined by common etiologic factors. Blood 2013; 121 (24) 4948-4954
    CrossrefPubMedGoogle Scholar
  • 22 Vaughan CJ, Gotto Jr AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 23 Ridker PM, Danielson E, Fonseca FA. , et al; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373 (9670): 1175-1182
    CrossrefPubMedGoogle Scholar
  • 24 Schäfer A, Fraccarollo D, Eigenthaler M. , et al. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 2005; 25 (05) 1071-1077
    CrossrefPubMedGoogle Scholar
  • 25 Gertz K, Laufs U, Lindauer U. , et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34 (02) 551-557
    CrossrefPubMedGoogle Scholar
  • 26 Laufs U, Gertz K, Huang P. , et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31 (10) 2442-2449
    CrossrefPubMedGoogle Scholar
  • 27 Ni R, Peleg T, Gross PL. Atorvastatin delays murine platelet activation in vivo even in the absence of endothelial NO synthase. Arterioscler Thromb Vasc Biol 2012; 32 (11) 2609-2615
    CrossrefPubMedGoogle Scholar
  • 28 Hamada M, Sugimoto M, Matsui H. , et al. Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions. Thromb Haemost 2011; 105 (02) 313-320
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011; 8 (09) 502-512
    CrossrefPubMedGoogle Scholar
  • 30 Aoki I, Aoki N, Kawano K. , et al. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol 1997; 30 (01) 91-96
    CrossrefPubMedGoogle Scholar
  • 31 Puccetti L, Pasqui AL, Pastorelli M. , et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002; 32 (12) 901-908
    CrossrefPubMedGoogle Scholar
  • 32 Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000; 85 (03) 350-353
    CrossrefPubMedGoogle Scholar
  • 33 Puccetti L, Pasqui AL, Pastorelli M. , et al. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003; 90 (03) 476-482
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Haramaki N, Ikeda H, Takenaka K. , et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 2007; 27 (06) 1471-1477
    CrossrefPubMedGoogle Scholar
  • 35 Ural AU, Yilmaz MI, Avcu F, Yalcin A. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. Int J Hematol 2002; 76 (03) 279-283
    PubMedGoogle Scholar
  • 36 Ali FY, Armstrong PC, Dhanji AR. , et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009; 29 (05) 706-711
    CrossrefPubMedGoogle Scholar
  • 37 Biedermann JS, Cannegieter SC, Roest M. , et al. Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial. J Thromb Haemost 2016; 14 (07) 1404-1409
    CrossrefPubMedGoogle Scholar
  • 38 Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17 (02) 265-272
    CrossrefPubMedGoogle Scholar
  • 39 Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105 (15) 1756-1759
    CrossrefPubMedGoogle Scholar
  • 40 Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000; 149 (01) 111-116
    CrossrefPubMedGoogle Scholar
  • 41 Sen-Banerjee S, Mir S, Lin Z. , et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005; 112 (05) 720-726
    CrossrefPubMedGoogle Scholar
  • 42 Aikawa M, Rabkin E, Sugiyama S. , et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103 (02) 276-283
    CrossrefPubMedGoogle Scholar
  • 43 Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22 (04) 692-698
    CrossrefPubMedGoogle Scholar
  • 44 Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003; 167 (02) 187-194
    CrossrefPubMedGoogle Scholar
  • 45 Nagata K, Ishibashi T, Sakamoto T. , et al. Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. Atherosclerosis 2002; 163 (01) 39-47
    CrossrefPubMedGoogle Scholar
  • 46 Camera M, Toschi V, Comparato C. , et al. Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb Haemost 2002; 87 (04) 748-755
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Szczeklik A, Musiał J, Undas A. , et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33 (05) 1286-1293
    CrossrefPubMedGoogle Scholar
  • 48 Cortellaro M, Cofrancesco E, Arbustini E. , et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002; 88 (01) 41-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Morishita E, Minami S, Ishino C. , et al. Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. J Atheroscler Thromb 2002; 9 (01) 72-77
    CrossrefPubMedGoogle Scholar
  • 50 Porreca E, Di Febbo C, Amore C. , et al. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb Haemost 2000; 84 (05) 789-793
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Morishita E, Asakura H, Saito M. , et al. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Atherosclerosis 2001; 154 (01) 203-212
    CrossrefPubMedGoogle Scholar
  • 52 Ferro D, Basili S, Alessandri C, Mantovani B, Cordova C, Violi F. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. Lancet 1997; 350 (9086): 1222
    CrossrefPubMedGoogle Scholar
  • 53 Krysiak R, Okopien B. Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia. Pharmacology 2013; 92 (3-4): 187-190
    CrossrefPubMedGoogle Scholar
  • 54 Steiner S, Speidl WS, Pleiner J. , et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111 (14) 1841-1846
    CrossrefPubMedGoogle Scholar
  • 55 Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C. Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol 2006; 106 (03) 333-337
    CrossrefPubMedGoogle Scholar
  • 56 Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103 (18) 2248-2253
    CrossrefPubMedGoogle Scholar
  • 57 Undas A, Celinska-Löwenhoff M, Brummel-Ziedins KE, Brozek J, Szczeklik A, Mann KG. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2005; 25 (07) 1524-1525
    CrossrefPubMedGoogle Scholar
  • 58 Joukhadar C, Klein N, Prinz M. , et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001; 85 (01) 47-51
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Ordulu E, Erdogan O. Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. Int J Cardiol 2008; 128 (02) 282-284
    CrossrefPubMedGoogle Scholar
  • 60 Musiał J, Undas A, Undas R, Brozek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost 2001; 85 (02) 221-225
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Cipollone F, Mezzetti A, Porreca E. , et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106 (04) 399-402
    CrossrefPubMedGoogle Scholar
  • 62 Sanguigni V, Pignatelli P, Lenti L. , et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111 (04) 412-419
    CrossrefPubMedGoogle Scholar
  • 63 Kaba NK, Francis CW, Moss AJ. , et al; THROMBO Investigators. Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004; 2 (05) 718-725
    CrossrefPubMedGoogle Scholar
  • 64 Tonkin AM, Blankenberg S, Kirby A. , et al; LIPID study investigators. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. Int J Cardiol 2015; 201: 499-507
    CrossrefPubMedGoogle Scholar
  • 65 Sahebkar A, Serban C, Ursoniu S. , et al; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost 2016; 115 (03) 520-532
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Sahebkar A, Serban C, Mikhailidis DP. , et al; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost 2015; 114 (03) 546-557
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Biedermann JS, Kruip MJHA, van der Meer FJ. , et al. Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. Eur Heart J 2018; 39 (19) 1740-1747
    CrossrefPubMedGoogle Scholar
  • 68 Bevilacqua M, Bettica P, Milani M. , et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79 (01) 84-87
    CrossrefPubMedGoogle Scholar
  • 69 Dangas G, Badimon JJ, Smith DA. , et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33 (05) 1294-1304
    CrossrefPubMedGoogle Scholar
  • 70 Dangas G, Smith DA, Unger AH. , et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83 (05) 688-692
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Bruni F, Pasqui AL, Pastorelli M. , et al. Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. Int J Cardiol 2004; 95 (2-3): 269-274
    CrossrefPubMedGoogle Scholar
  • 72 Tetik S, Ak K, Sahin Y. , et al. Postoperative statin therapy attenuates the intensity of systemic inflammation and increases fibrinolysis after coronary artery bypass grafting. Clin Appl Thromb Hemost 2011; 17 (05) 526-531
    CrossrefPubMedGoogle Scholar
  • 73 Ushiroyama T, Nosaka S, Ueki M. Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women. Int J Cardiol 2006; 113 (01) 66-75
    CrossrefPubMedGoogle Scholar
  • 74 Liu L, Zhao SP, Zhou HN, Li QZ, Li JX. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50 (01) 50-55
    CrossrefPubMedGoogle Scholar
  • 75 Undas A, Kaczmarek P, Sladek K. , et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102 (06) 1176-1182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Adams NB, Lutsey PL, Folsom AR. , et al. Statin therapy and levels of hemostatic factors in a healthy population: the multi-ethnic study of atherosclerosis. J Thromb Haemost 2013; 11 (06) 1078-1084
    CrossrefPubMedGoogle Scholar
  • 77 Sahebkar A, Catena C, Ray KK. , et al. Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost 2016; 116 (01) 162-171
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Kessinger CW, Kim JW, Henke PK. , et al. Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring. PLoS One 2015; 10 (02) e0116621
    CrossrefPubMedGoogle Scholar
  • 79 Patterson KA, Zhang X, Wrobleski SK. , et al. Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res 2013; 131 (03) 268-276
    CrossrefPubMedGoogle Scholar
  • 80 Grady D, Wenger NK, Herrington D. , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med 2000; 132 (09) 689-696
    PubMedGoogle Scholar
  • 81 Lijfering WM, Biedermann JS, Kruip MJ, Leebeek FW, Rosendaal FR, Cannegieter SC. Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility. Expert Rev Hematol 2016; 9 (11) 1023-1030
    CrossrefPubMedGoogle Scholar
  • 82 Rahimi K, Bhala N, Kamphuisen P. , et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012; 9 (09) e1001310
    CrossrefPubMedGoogle Scholar
  • 83 Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326 (7404): 1423
    CrossrefPubMedGoogle Scholar
  • 84 Nissen SE, Nicholls SJ, Sipahi I. , et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295 (13) 1556-1565
    CrossrefPubMedGoogle Scholar
  • 85 Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 2017; 4 (02) e83-e93
    PubMedGoogle Scholar
  • 86 Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011; 128 (05) 422-430
    CrossrefPubMedGoogle Scholar
  • 87 Thomsen RW. The lesser known effects of statins: benefits on infectious outcomes may be explained by “healthy user” effect. BMJ 2006; 333 (7576): 980-981
    CrossrefPubMedGoogle Scholar
  • 88 van Rein N, Cannegieter SC, le Cessie S. , et al. Statins and risk of bleeding: an analysis to evaluate possible bias due to prevalent users and healthy user aspects. Am J Epidemiol 2016; 183 (10) 930-936
    CrossrefPubMedGoogle Scholar
  • 89 Nguyen CD, Andersson C, Jensen TB. , et al. Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study. BMJ Open 2013; 3 (11) e003135
    CrossrefPubMedGoogle Scholar
  • 90 Schmidt M, Cannegieter SC, Johannesdottir SA, Dekkers OM, Horváth-Puhó E, Sørensen HT. Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. J Thromb Haemost 2014; 12 (08) 1207-1215
    CrossrefPubMedGoogle Scholar
  • 91 Smith NL, Harrington LB, Blondon M. , et al. The association of statin therapy with the risk of recurrent venous thrombosis. J Thromb Haemost 2016; 14 (07) 1384-1392
    CrossrefPubMedGoogle Scholar
  • 92 Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J 2017; 38 (20) 1608-1612
    CrossrefPubMedGoogle Scholar
  • 93 Brookhart MA, Patrick AR, Dormuth C. , et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166 (03) 348-354
    CrossrefPubMedGoogle Scholar